학술논문
Two cases of acute‐onset cystoid macular edema and serous retinal detachment associated with combined use of encorafenib and binimetinib for advanced melanoma: A possible confounding risk for drug intolerance
Document Type
Report
Author
Source
Journal of Cutaneous Immunology and Allergy. December 2023, Vol. 6 Issue 6, p231, 3 p.
Subject
Language
English
Abstract
INTRODUCTION In Japan, an encorafenib/binimetinib combination therapy was approved in 2019 for BRAF‐mutated, advanced melanoma, following dabrafenib/trametinib. While the BRAF/MEK inhibitors have evoked dramatic clinical efficacy on incurable melanoma, serous [...]
: While combined use of BRAF/MEK inhibitors has elicited dramatic clinical efficacy in incurable melanoma, drug‐associated retinopathy has become an emerging adverse event. We present two Japanese men with advanced melanoma who developed visual impairment due to serous retinal detachments (SRDs) with cystoid macular edema (CME) immediately after initial administration of encorafenib/binimetinib, a BRAF and MEK inhibitor. One case had drug‐intolerable retinopathy on repeat dosing. Both cases were switched to another BRAF/MEK inhibitors, dabrafenib/trametinib, with no recurrence of SRDs. Co‐existing CME may be a confounding risk for the early development of SRDs with encorafenib/binimetinib therapy, providing attention during drug administration.
: While combined use of BRAF/MEK inhibitors has elicited dramatic clinical efficacy in incurable melanoma, drug‐associated retinopathy has become an emerging adverse event. We present two Japanese men with advanced melanoma who developed visual impairment due to serous retinal detachments (SRDs) with cystoid macular edema (CME) immediately after initial administration of encorafenib/binimetinib, a BRAF and MEK inhibitor. One case had drug‐intolerable retinopathy on repeat dosing. Both cases were switched to another BRAF/MEK inhibitors, dabrafenib/trametinib, with no recurrence of SRDs. Co‐existing CME may be a confounding risk for the early development of SRDs with encorafenib/binimetinib therapy, providing attention during drug administration.